MAPT and Alzheimer disease: Sulforaphane suppressed tau hyper-phosphorylation and improved cognitive deficits in mouse models of AD, as well as in models of dementia-associated vascular cognitive impairment and metabolic dysfunction-driven diabetes mellitus (Hou et al., 2018; Li et al., 2025; Lee et al., 2018; Pu et al., 2018).